17-Alpha hydroxyprogesterone for reducing preterm labor

MOspace/Manakin Repository

Breadcrumbs Navigation

17-Alpha hydroxyprogesterone for reducing preterm labor

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/9448

[-] show simple item record

dc.contributor.author Skladzien, Stephanie en_US
dc.contributor.author Dresang, Lee T. en_US
dc.date.accessioned 2010-12-22T20:11:25Z
dc.date.available 2010-12-22T20:11:25Z
dc.date.issued 2010-10
dc.identifier.citation Evidence Based Practice 13(10): 11. en_US
dc.identifier.uri http://hdl.handle.net/10355/9448
dc.description.abstract Supplementation with intramuscular 17-alpha hydroxyprogesterone caproate (17P) significantly reduces the incidence of preterm delivery for women at increased risk of preterm birth. All women with a singleton pregnancy and a history of prior preterm birth should be offered weekly injections. Additional studies are needed to investigate use in women with a short cervix, multiple gestations, and in arrest of preterm labor. Complete maternal and fetal safety profiles, as well as ideal dose, route of administration, and duration of treatment, are also evolving. en_US
dc.language.iso en_US en_US
dc.publisher Family Physicians Inquiries Network en_US
dc.relation.ispartof Evidence Based Practice 13(10): 11. en_US
dc.subject delivery rates en_US
dc.subject progesterone therapy en_US
dc.subject.lcsh Labor (Obstetrics) en_US
dc.subject.lcsh Delivery (Obstetrics) en_US
dc.subject.lcsh Progesterone en_US
dc.title 17-Alpha hydroxyprogesterone for reducing preterm labor en_US
dc.type Article en_US
dc.relation.ispartofcommunity University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. Evidence Based Practice. en_US
dc.relation.ispartofcollection Evidence Based Practice, 2010 en_US


This item appears in the following Collection(s)

[-] show simple item record